Cancer Research UK and Breakthrough Breast Cancer partner on Stand Up To Cancer

first_img Tagged with: Cancer Research UK Events “There is so much more to be done in order to stop breast cancer for good, but collaboration is key to getting us there. It is by bringing the best minds together, and working with a common goal, that we can truly reach the point where breast cancer, and all cancers, are stopped in their tracks.”March On Cancer™New to Stand Up To Cancer this year is March On Cancer™, a sponsored night-time walking experience. On Saturday 11th October at 7.30pm, thousands of people will come together as “a collective show of force against cancer” in 15 simultaneous nationwide events in city centres across the UK.Stand Up To Cancer TV advert 2014[youtube height=”450″ width=”800″]https://www.youtube.com/watch?v=cEQYu75eTls[/youtube] Cancer Research UK and Breakthrough Breast Cancer partner on Stand Up To Cancer Cancer Research UK and Breakthrough Breast Cancer are working as research partners for Stand Up To Cancer, the joint national fundraising campaign from Cancer Research UK and Channel 4.The two charities will combine funds for selected translational breast cancer research projects with the aim of bringing new breast cancer treatments to patients faster.Stand Up To Cancer is a fundraising initiative, but it is also designed to stimulate collaboration in the cancer research community.Claire Rowney, Director of UK Stand Up To Cancer at Cancer Research UK said:“We are thrilled to be able to announce this partnership between two major cancer charities. Our Stand Up To Cancer campaign is all about bringing the nation together to make a stand and encouraging collaborative working to help bring treatments to patients faster”.Chris Askew, Chief Executive at Breakthrough Breast Cancer, added: Advertisement [message_box title=”About Stand Up To Cancer” color=”blue”]Founded in the US in 2008, Stand Up To Cancer has harnessed the support of the entertainment industry to generate millions in pledges for cancer research.The telethon came to the UK on Channel 4 in 2012 to raise funds to accelerate innovative cancer research and get new treatments to patients more quickly. In 2012, Stand Up To Cancer’s fundraising total exceeded £8 million, funding 12 clinical trials across the UK and this year’s aim is to do even better.The 2014 campaign is encouraging people to join the frontline against cancer this autumn by fundraising, buying merchandise, joining March On Cancer™ and tuning in to the live TV show on Channel 4 on Friday 17th October.[/message_box] Howard Lake | 7 October 2014 | News  62 total views,  1 views today AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis About Howard Lake Howard Lake is a digital fundraising entrepreneur. Publisher of UK Fundraising, the world’s first web resource for professional fundraisers, since 1994. Trainer and consultant in digital fundraising. Founder of Fundraising Camp and co-founder of GoodJobs.org.uk. Researching massive growth in giving.last_img read more

The stories that shaped Oxford life in 2015-2016

first_imgThere was a period of several weeks near the beginning of Hilary when all anyone could talk about was Rhodes Must Fall. From Junior Common Rooms to bars, college dinners to social media, Oxford was dominated by RMF. That Oriel finally decided to retain its controversial statue of colonialist Cecil Rhodes, one suspects, will not diminish the lasting legacy of the protest group.University news can often be tremendously dull – I cannot count how many times Cherwell has been forced to rely on academic reports to fill the space in lieu of more interesting content. But 2015-2016 has been an exciting year at Oxford, at least for this former news editor. Even beyond RMF, we have had more than our fair share of stories that have gotten the University buzzing and which have been picked up by the national media.Consider this term’s referendum on whether to disaffiliate from the National Union of Students over the election of Malia Bouattia or last term’s allegations of anti-Semitism within the Oxford University Labour Club. Microcosms of a national debate over anti-Semitism within the ranks of the political left, the two events forced Oxford to grapple with weighty issues, such as how to balance the needs of different minority groups. Indeed, the rights of members of underrepresented communities – black and minority ethnic students, Jewish students, queer students – have been at the fore this year.In other news, political correctness movements and discussion of the limits of free speech have seemed ubiquitous, with Michaelmas seeing a healthy dose of debate over ‘no platforming’. And unfortunately, the formal installation of Oxford’s first female Vice-Chancellor was overshadowed the remarks of Chancellor Chris Patten, who has repeatedly provoked ire for comments about RMF, safe spaces and admissions quotas.To the not-so-great shock of all observers, Oxford continues to underperform in terms of access. The proportion of students admitted from state schools, just over 50 per cent, is unimproved from previous years. Dismally, only 38 students of black or black British ethnic background were accepted for entry in 2015. Nonetheless, we have retained our strong place in international university rankings, receiving second place from Times Higher Education (although only sixth in the QS World University Ranking).There have been other, more light-hearted stories too, for instance about a Green Templeton professor who lives much of his life as different animals. And at Christ Church in February, after a graduate student initiated confrontations over the college’s LGBTQ flag and quoted an anti-homosexual Corinthians verse, the college banded together in solidarity to support the queer community.As for Rhodes Must Fall, despite issuing a seven-point manifesto and organising a march at the end of term, the group has largely gone mum. We will have to wait until October to see what comes next.last_img read more

FDA may use strain change model for evaluating H1N1 vaccines

first_imgJul 23, 2009 (CIDRAP News) – The Food and Drug Administration (FDA) may review vaccines for the novel H1N1 influenza virus the same way it evaluates the annual updates of seasonal flu vaccines, which would probably lead to faster FDA approval than occurs with brand-new products, an FDA official said in the wake of an FDA advisory committee meeting today.FDA spokeswoman Peper Long said the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) expressed support for an FDA staff recommendation to handle the H1N1 vaccines the way seasonal flu vaccines are handled. The committee met today to publicly air H1N1 vaccine issues.Five companies—Sanofi Pasteur, Novartis, CSL Ltd., GlaxoSmithKline (GSK), and MedImmune—are rushing to make H1N1 influenza vaccines for the US government and are launching or preparing to launch clinical trials. US officials want trial data as soon as possible so they can approve vaccines in time for a potential renewed surge of the virus this fall after children return to school.The committee didn’t make a formal recommendation about how to regulate the new vaccines, but a consensus in favor of using the seasonal vaccine approach emerged, Long told CIDRAP News.Long noted that manufacturers with established seasonal flu vaccines file a supplemental application each year after changing one or more of the three flu strains in the vaccine, in line with FDA recommendations. A “strain change supplement” usually doesn’t require new clinical data, though some immunogenicity and safety data usually are available, she said.The other licensing pathways for vaccines are to file a biologics license application (BLA), involving a formal process with full clinical trials, or to seek an emergency use authorization (EUA). In declared public health emergencies, the FDA can provide an EUA for products whose effectiveness has not yet been fully demonstrated.”The third way is a strain change supplement, which is how flu vaccines are approved every year,” Long said. “That doesn’t usually require new clinical data.””A strain change supplement will allow us to license a vaccine based on our experience evaluating vaccines over the years, so if necessary we can have a vaccine ready to go,” she said. With clinical trials starting now, some results are likely to be available by the time the vaccine is needed, she added.”We’ll start to see some first-round data by September,” Long said.The committee “pretty well agreed” with the strain change regulatory approach, she said. However, she said this approach would be possible only for vaccines that are not paired with dose-sparing adjuvants.The government has ordered supplies of adjuvants made by Novartis and GSK, but no US-licensed vaccines contain those adjuvants and, hence, their use will require special testing and evaluation.Long said a GSK official at today’s meeting discussed plans to test the company’s vaccine with an adjuvant. “That couldn’t be approved as a strain change supplement with FDA; that would have to fall under a regular BLA or an emergency use authorization,” she said.She emphasized that a final decision on how to regulate the H1N1 vaccines will be up to the secretary of the Department of Health and Human Services and that the proposal to use the strain-change approach assumes that H1N1 vaccines will be needed before full clinical testing can be completed.”We’re preparing for a lot of contingencies, and each step along the way is its own risk-benefit analysis,” she commented.The five vaccine makers are all growing their vaccines in chicken eggs, the conventional production method in use for decades. Four of the five are dealing with low yields of the vaccine—half or less of what they typically get with seasonal flu vaccines, according to recent reports.However, MedImmune is getting a much better yield with its live attenuated vaccine, which is given as a nasal spray. Company officials who were at today’s meeting said they could make more doses than they have spray bottles to deliver, according to an Associated Press report.See also: Jul 23 VRBPAC meeting informationBriefing document for meetingGeneral information about the committeelast_img read more